Eton Pharmaceuticals (ETON) EBIT Margin (2019 - 2026)

Eton Pharmaceuticals has disclosed EBIT Margin across 8 years of filings, most recently posting 34.04% for Q2 2026.

• In Q2 2026, EBIT Margin rose 4183.0% year-over-year to 34.04%; the TTM figure through Jun 2026 stood at 12.39% (up 1378.0% YoY), while the FY2025 annual figure was 1.06%, up 560.0% from the prior year.
• EBIT Margin came in at 34.04% for Q2 2026 at Eton Pharmaceuticals, up from 11.58% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 34.04% in Q2 2026 to a low of 233.78% in Q1 2022.
• Average EBIT Margin over 5 years is 23.03%, with a median of 7.79% recorded in 2025.
• The largest YoY upside for EBIT Margin was 66452 bps in 2022 against a maximum downside of 27886 bps in 2022.
• Over 5 years, EBIT Margin stood at 12.5% in 2022, then tumbled by 318 bps to 27.25% in 2023, then surged by 120 bps to 5.4% in 2024, then soared by 114 bps to 11.58% in 2025, then soared by 194 bps to 34.04% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 34.04% in Q2 2026, 11.58% in Q4 2025, and 6.07% in Q3 2025.